Rockwell Medical (RMTI) announced that the Amended and Restated Product Purchase Agreement dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States has been extended through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMTI:
- Rockwell Med Appoints Joseph Dawson to Board
- Rockwell Medical: Strategic Growth Amidst Transition and Stability
- Strategic Developments and Financial Projections Justify Buy Rating for Rockwell Medical
- Rockwell Medical price target lowered to $2.50 from $3 at H.C. Wainwright
- Rockwell Medical Reports Q3 2025 Earnings and Strategic Moves